Premium
The use of DDAVP in children with bleeding disorders
Author(s) -
BenAmi Tal,
RevelVilk Shoshana
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24335
Subject(s) - medicine , desmopressin , vasopressin , blood cancer , bleeding time , platelet , von willebrand factor , pediatrics , von willebrand disease , gastroenterology , cancer , platelet aggregation
Desmopressin (1‐deamino‐8‐ D ‐arginine vasopressin, DDAVP) has been used in children with von Willebrand disease (VWD) and Hemophilia A for almost 35 years. This treatment has substantially lowered the number of children exposed to human plasma derived products, with a good safety profile, and at very low cost. The response to DDAVP has been shown to be associated with age, baseline factor level, and genetic mutations. A DDAVP challenge test is recommended. DDAVP has also been used to prevent and treat bleeding episodes in children with platelet function defects and other disorders associated with bleeding tendency. Pediatr Blood Cancer 2012; 60: S41–S43. © 2012 Wiley Periodicals, Inc.